Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma.
Roddie C, Lekakis LJ, Marzolini MAV, Ramakrishnan A, Zhang Y, Hu Y, Peddareddigari VGR, Khokhar N, Chen R, Basilico S, Raymond M, Vargas FA, Duffy K, Brugger W, O'Reilly MA, Wood L, Linch DC, Peggs KS, Bachier C, Budde EL, Lee Batlevi C, Bartlett N, Irvine D, Tholouli E, Osborne W, Ardeshna KM, Pule MA. Roddie C, et al. Among authors: tholouli e. Blood. 2023 May 18;141(20):2470-2482. doi: 10.1182/blood.2022018598. Blood. 2023. PMID: 36821767 Free PMC article.
Salvage use of allogeneic hematopoietic stem cell transplantation after reduced intensity conditioning from unrelated donors in multiple myeloma. A study by the Plasma Cell Disorders subcommittee of the European Group for Blood and Marrow Transplant Chronic Malignancies Working Party.
Sobh M, Michallet M, Dubois V, Iacobelli S, Koster L, Van Biezen A, Fegueux N, Tabrizi R, Finke J, El-Cheikh J, Schipperus M, Meijer E, von dem Borne P, Petersen E, Russell N, Tholouli E, Passweg J, Garban F, Maertens J, Chevalier P, Maillard N, Volin L, Francois S, Lioure B, Beguin Y, Gluckman E, Ruggeri A, Garderet L, Kröger N. Sobh M, et al. Among authors: tholouli e. Haematologica. 2017 Jul;102(7):e271-e274. doi: 10.3324/haematol.2017.165399. Epub 2017 Apr 20. Haematologica. 2017. PMID: 28428268 Free PMC article. No abstract available.
Impact of pre-transplant co-morbidities on outcome after alemtuzumab-based reduced intensity conditioning allo-SCT in elderly patients: a British Society of Blood and Marrow Transplantation study.
Nikolousis E, Nagra S, Pearce R, Perry J, Kirkland K, Byrne J, Dignan F, Tholouli E, Gilleece M, Russell N, Littlewood T, Cook M, Peniket A, Shaw BE, Cook G, Craddock C. Nikolousis E, et al. Among authors: tholouli e. Bone Marrow Transplant. 2015 Jan;50(1):82-6. doi: 10.1038/bmt.2014.215. Epub 2014 Oct 6. Bone Marrow Transplant. 2015. PMID: 25285801
Presence of donor-encoded centromeric KIR B content increases the risk of infectious mortality in recipients of myeloablative, T-cell deplete, HLA-matched HCT to treat AML.
Bultitude WP, Schellekens J, Szydlo RM, Anthias C, Cooley SA, Miller JS, Weisdorf DJ, Shaw BE, Roberts CH, Garcia-Sepulveda CA, Lee J, Pearce RM, Wilson MC, Potter MN, Byrne JL, Russell NH, MacKinnon S, Bloor AJ, Patel A, McQuaker IG, Malladi R, Tholouli E, Orchard K, Potter VT, Madrigal JA, Mayor NP, Marsh SGE. Bultitude WP, et al. Among authors: tholouli e. Bone Marrow Transplant. 2020 Oct;55(10):1975-1984. doi: 10.1038/s41409-020-0858-9. Epub 2020 Mar 13. Bone Marrow Transplant. 2020. PMID: 32203258 Free PMC article.
Letermovir prophylaxis in T-cell-depleted transplants: breakthrough and rebound infections in the postmarketing setting.
Marzolini MAV, Mehra V, Thomson KJ, Tholouli E, Bloor AJC, Parker A, Lovell R, Orchard K, Publicover A, Nicholson E, Snowden JA, Byrne J, Khan A, Gilleece MH, Errico G, Lozano S, Hurst E, Duncan N, Pirrie J, Crea P, Carpenter B, Pagliuca A, Peggs KS. Marzolini MAV, et al. Among authors: tholouli e. Blood Adv. 2021 Nov 9;5(21):4500-4503. doi: 10.1182/bloodadvances.2021005637. Blood Adv. 2021. PMID: 34614515 Free PMC article. No abstract available.
Severe presentations and high mortality from SARS-CoV-2 in patients undergoing chimeric antigen receptor (CAR-T) therapy: a UK NCCP analysis.
Cheok KPL, Kirkwood AA, Menne T, Tholouli E, Chaganti S, Mathew A, Uttenthal B, Russell J, Irvine D, Johnson R, Nicholson E, Bazin J, Townsend W, Kuhnl A, O'Reilly M, Sanderson R, Patel A, Roddie C. Cheok KPL, et al. Among authors: tholouli e. Leuk Lymphoma. 2022 Aug;63(8):1980-1984. doi: 10.1080/10428194.2022.2057487. Epub 2022 Apr 28. Leuk Lymphoma. 2022. PMID: 35481791 No abstract available.
A national service for delivering CD19 CAR-Tin large B-cell lymphoma - The UK real-world experience.
Kuhnl A, Roddie C, Kirkwood AA, Tholouli E, Menne T, Patel A, Besley C, Chaganti S, Sanderson R, O'Reilly M, Norman J, Osborne W, Bloor A, Lugthart S, Malladi R, Patten PEM, Neill L, Martinez-Cibrian N, Kennedy H, Phillips EH, Jones C, Sharplin K, El-Sharkawi D, Latif AL, Mathew A, Uttenthal B, Stewart O, Marzolini MAV, Townsend W, Cwynarski K, Ardeshna K, Ardavan A, Robinson K, Pagliuca A, Collins GP, Johnson R, McMillan A. Kuhnl A, et al. Among authors: tholouli e. Br J Haematol. 2022 Aug;198(3):492-502. doi: 10.1111/bjh.18209. Epub 2022 Apr 29. Br J Haematol. 2022. PMID: 35485402
Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma.
Roddie C, Neill L, Osborne W, Iyengar S, Tholouli E, Irvine D, Chaganti S, Besley C, Bloor A, Jones C, Uttenthal B, Johnson R, Sanderson R, Cheok K, Marzolini M, Townsend W, O'Reilly M, Kirkwood AA, Kuhnl A. Roddie C, et al. Among authors: tholouli e. Blood Adv. 2023 Jun 27;7(12):2872-2883. doi: 10.1182/bloodadvances.2022009019. Blood Adv. 2023. PMID: 36724512 Free PMC article.
83 results